Research programme: ADAM8 inhibitors - Cancer Research Technology/Medivir

Drug Profile

Research programme: ADAM8 inhibitors - Cancer Research Technology/Medivir

Alternative Names: ADAM8 inhibitors - Medivir

Latest Information Update: 24 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kings College London
  • Developer Cancer Research Technology; Kings College London; Medivir AB; TransMIT Gesellschaft fur Technologietransfer mbH
  • Class Small molecules
  • Mechanism of Action ADAM protein inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Pancreatic cancer

Most Recent Events

  • 17 Nov 2015 Medivir terminates its licence for ADAM8 inhibitors in Sweden
  • 17 Nov 2015 Discontinued for Cancer in Sweden (unspecified route)
  • 17 Nov 2015 Discontinued for Pancreatic cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top